CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

To assess the effect of CPG 7909 Injection on Cutaneous T-cell lymphoma and the safety of CPG 7909 Injection in patients with this cancer.

Phase 1/Phase 2

Pfizer